Dole PLC

Dole plc reported second-quarter 2026 adjusted earnings per share of 46 cents, missing the Zacks Consensus Estimate of 50 cents and down 16.4% from 55 cents a year ago. Revenue increased 2.9% year over year to $2.5 billion but fell short of the $2.52 billion consensus. Fresh Fruit adjusted EBITDA declined 30.9% to $50.3 million, pressured by higher fruit sourcing, fuel, and shipping costs, while Diversified Fresh Produce – Americas & ROW saw adjusted EBITDA rise 33.8% to $20.6 million on strong volumes. The company maintained its full-year 2026 adjusted EBITDA guidance of approximately $400 million and completed the Ecuador port sale after quarter-end, generating expected net proceeds of about $95 million.

Tenax Therapeutics and Sionna Therapeutics shares plunged in premarket trading after their respective clinical trials failed, while MarineMax jumped on a reported buyout by Blackstone-owned Safe Harbor Marinas. Tenax stock fell 84.2% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, showing no statistically significant improvement in six-minute walk distance versus placebo with a p-value of 0.63. Sionna shares dropped 92.1% after its Phase 2a trial of SION-719 failed to demonstrate meaningful CFTR function improvement, with a placebo-adjusted sweat chloride change of just -1.0 mmol/L and a p-value of 0.7. MarineMax surged more than 34% after Reuters reported Safe Harbor is close to acquiring the boat retailer for $1.5 billion including debt, or about $53 per share in cash, a substantial premium to Friday's close of $35.68. AAON gained over 10.6% after its second-quarter results apparently beat expectations, while Silence Therapeutics rose 16.2% ahead of a conference call on its Phase 2 SANRECO trial. Dole fell 4.2% after missing second-quarter earnings and revenue estimates, and AirSculpt Technologies dropped 18.4% on weaker quarterly results with revenue down 3% year-over-year.

Dole plc is scheduled to report second-quarter 2026 results on August 10 before market open. The consensus revenue estimate is $2.5 billion, implying a 3.7% increase from the year-ago quarter, while the consensus earnings estimate is 50 cents per share, reflecting a nearly 9% decline. The company has faced elevated fruit sourcing costs due to weather-related supply constraints and higher fuel, freight, fertilizer, and packaging costs stemming from the Middle East conflict, which are expected to have pressured profitability. Dole has also benefited from strong fresh produce demand, disciplined pricing, and investments in its vertically integrated supply chain and high-growth categories like cherries and citrus. The stock has a forward price-to-earnings ratio of 9.73, below the industry average of 14.51, and its shares have lost 12.1% over the past six months.